Directed new share issue in Oncopeptides AB (SE) — SEK 1.4 billion

Carnegie acted as joint bookrunner in the directed new share issue of 12,295,000 million shares at a subscription price of SEK 115 per share. Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. May 2020.